Document is current
Any future updates will be listed below
-
Authors
Ezzedine, Khaled https://orcid.org/0000-0002-5468-4589
Harris, John E. https://orcid.org/0000-0002-7815-6430
Hamzavi, Iltefat H. https://orcid.org/0000-0002-3137-5601
Bibeau, Kristen https://orcid.org/0000-0002-6871-2333
Gao, Jessy
Ren, Haobo https://orcid.org/0000-0002-4694-2795
van Geel, Nanja https://orcid.org/0000-0002-3249-8195
-
Funding
Funding for this research was provided by:
Incyte
- License Information
-
More Information
Article History
Received: 30 January 2025
Accepted: 20 May 2025
First Online: 4 July 2025
Declarations
:
: Khaled Ezzedine is a consultant for AbbVie, Incyte, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi, and Viela Bio. John E. Harris has served as a consultant for AbbVie, Aclaris Therapeutics, BiologicsMD, EMD Serono, Genzyme/Sanofi, Janssen, Pfizer, Rheos Medicines, Sun Pharmaceuticals, TeVido BioDevices, The Expert Institute, 3rd Rock Ventures, and Villaris Therapeutics; has served as an investigator for Aclaris Therapeutics, Celgene, Dermira, EMD Serono, Genzyme/Sanofi, Incyte, LEO Pharma, Pfizer, Rheos Medicines, Stiefel/GlaxoSmithKline, Sun Pharmaceuticals, TeVido BioDevices, and Villaris Therapeutics; holds equity in Aldena Therapeutics, NIRA Biosciences, Rheos Medicines, TeVido BioDevices, and Villaris Therapeutics; is a scientific founder of Aldena Therapeutics, NIRA Biosciences, and Villaris Therapeutics; and has patents pending for IL-15 blockade for treatment of vitiligo, JAK inhibition with light therapy for vitiligo, and CXCR3 antibody depletion for treatment of vitiligo. Iltefat H. Hamzavi has served as a consultant and investigator for AbbVie, Almirall, Avita, Boehringer Ingelheim, Galderma, Incyte, Janssen, Novartis, Pfizer, Sonoma, UCB, Union Therapeutics, and Vimela; immediate past president of the HS Foundation; and a board member of the Global Vitiligo Foundation. Kristen Bibeau was an employee and shareholder of Incyte at the time of this study. Jessy Gao and Haobo Ren are employees and shareholders of Incyte. Nanja van Geel is a consultant and/or investigator for AbbVie, Bristol Myers Squibb, Idorsia Pharmaceuticals, Incyte, Merck/MSD, Pfizer, and Sun Pharma; and is Chair of the Vitiligo Task Force for the European Academy of Dermatology and Venereology (EADV).
: The study was performed in accordance with the Declaration of Helsinki and in adherence to the study protocol and local regulatory requirements. All survey participants provided informed consent at screening and could withdraw consent at any time. The study protocol received an exemption from the Western Institutional Review Board, given the survey procedures and use of deidentified data.
